DaVita (NYSE:DVA) Price Target Cut to $216.00 by Analysts at Barclays

DaVita (NYSE:DVA) had its price target reduced by equities research analysts at Barclays from $224.00 to $216.00 in a report issued on Monday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price target suggests a potential upside of 16.52% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. Truist Financial reduced their price objective on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. TD Cowen boosted their target price on DaVita from $220.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $265.00 price target on shares of DaVita in a report on Wednesday, August 5th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $235.86.

DaVita Stock Performance

DVA traded down $2.13 during trading on Monday, hitting $185.37. The stock had a trading volume of 881,900 shares, compared to its average volume of 895,771. The firm has a market capitalization of $11.66 billion, a P/E ratio of 13.65, a PEG ratio of 0.48 and a beta of 0.87. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49. The company’s 50-day moving average price is $181.36 and its 200 day moving average price is $176.50.

DaVita (NYSE:DVA) last released its earnings results on Thursday, October 29th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.57 by $0.25. The company had revenue of $3.58 billion during the quarter, compared to analysts’ expectations of $3.52 billion. DaVita had a net margin of 6.49% and a negative return on equity of 225.93%. The business’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the business earned $2.51 EPS. As a group, equities analysts expect that DaVita will post 14.74 earnings per share for the current fiscal year.

Institutional Trading of DaVita

A number of institutional investors have recently added to or reduced their stakes in the stock. CoreCap Advisors LLC increased its holdings in DaVita by 161.7% in the third quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock valued at $27,000 after buying an additional 97 shares in the last quarter. Root Financial Partners LLC lifted its position in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares during the period. Provenance Wealth Advisors LLC purchased a new stake in shares of DaVita during the 3rd quarter worth approximately $30,000. Western Wealth Management LLC purchased a new stake in shares of DaVita during the 1st quarter worth approximately $60,000. Finally, Compass Financial Management LLC acquired a new stake in shares of DaVita in the 2nd quarter worth approximately $72,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.